Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More News From Fortune Week

Bank of America 2Q profits jump 33 percent due to tax law

Jul 16, 2018

NEW YORK — Bank of America is reporting a 33 percent jump in second-quarter profits as it cut expenses and benefited from the new tax law. The banking giant, based in Charlotte, North Carolina, said Monday it earned $6.78 billion, or 63 cents per share, up from $4.75 billion, or 44 cents a share, in the same period a year earlier. That's better than the per-share projections of 57 cents from industry analysts, according to a survey by FactSet. Bank of America benefited from rising interest rates. Net interest income across the bank rose $664 million, or 6 percent, compared...

Jared Kushner's family firm accused of pushing out tenants

Jul 16, 2018

NEW YORK — The hammering and drilling began just months after Jared Kushner's family real estate firm bought a converted warehouse apartment building in the hip, Williamsburg section of Brooklyn. Tenants say it started early in the morning and went on until nightfall, so loud that it drowned out normal conversation, so violent it rattled pictures off the walls. So much dust wafted through ducts and under doorways that it coated beds and clothes in closets. Rats crawled through holes in the walls. Workers with passkeys barged in unannounced. Residents who begged for relief got a standard reply, "We have...

Survey of economists: US sales and employment likely to grow

Jul 16, 2018

DETROIT — Most U.S. business economists expect corporate sales to grow over the next three months and hiring and pay to rise with them. But a majority of the economists surveyed by the National Association for Business Economics say the corporate tax cuts that the Trump administration pushed through Congress have yet to affect their plans for hiring or investment. The administration had promoted its tax cuts, which were heavily tilted toward corporations and wealthy individuals, as likely to raise worker pay and promote corporate investment and expansion over time. The NABE also said a majority of respondents from goods-producing...

US firm tried to enlist ambassadors to help Russian company

Jul 16, 2018

WASHINGTON — A U.S. lobbying firm sought to recruit the ambassadors of France, Germany and several other countries to demonstrate international support for severing Russian oligarch Oleg Deripaska's control of Rusal, the aluminum manufacturing giant sanctioned by Washington. Documents made public by the Justice Department show that Mercury LLC drafted messages for at least six envoys to send to senior U.S. government officials that expressed support for a plan to eliminate Deripaska's majority stake in the EN+ Group, the holding company that owns nearly 50 percent of Rusal. The records are the latest installment in a drama full of international...

AP FACT CHECK: Trump's Europe trip marked by inaccuracies

Jul 16, 2018

WASHINGTON — President Donald Trump shook things up at every turn in his trip to Europe, making statements on NATO, Britain, Germany and more that were meant to provoke, and they did. Accuracy was not always a hallmark of these pronouncements. A week in review: TRUMP: "I didn't criticize the prime minister." — news conference Friday with British Prime Minister Theresa May. THE FACTS: He criticized her. In an interview with Britain's Sun newspaper, he complained sharply about her approach to taking Britain out of the European Union and suggested she isn't living up to the will of voters who...